Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (5)

2020

  1. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

  2. Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial

    Drugs in Context, Vol. 9

  3. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

  2. Role of rivaroxaban in the prevention of atherosclerotic events

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 8, pp. 771-780